NFKB1 and B-cell chronic lymphocytic leukemia: GSEA analysis of RNAseq data from 6 patients before and after taking ruxolitinib as a single agent for 4 or 8 weeks (13) suggested CLL cells exhibited much stronger NFκB activity in the presence of ruxolitinib (Figure 1A).